Showing results (241-250 of 340) with videos related to
Sort By:
Pageof 34
The Lancet. Rheumatology|January 17, 2024
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS ProgramJingWei Li, Sunil V Badve, Zien Zhou, et al.Journal of the American Society of Nephrology : JASN|April 6, 2007
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trialWouter B A Eijkelkamp, Zhongxin Zhang, Giuseppe Remuzzi, et al.The Lancet. Diabetes & Endocrinology|January 18, 2016
Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trialHiddo J L Heerspink, Frederik Persson, Barry M Brenner, et al.Stroke|December 29, 2018
Canagliflozin and Stroke in Type 2 Diabetes MellitusZien Zhou, Richard I Lindley, Karin Rådholm, et al.Diabetes, Obesity & Metabolism|October 12, 2020
Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomesBrendon L Neuen, Clare Arnott, Vlado Perkovic, et al.Clinical Journal of the American Society of Nephrology : CJASN|October 10, 2015
Plasma Vitamin D Level and Change in Albuminuria and eGFR According to Sodium IntakeCharlotte A Keyzer, Hiddo J Lambers-Heerspink, Michel M Joosten, et al.Clinical Chemistry and Laboratory Medicine|November 22, 2014
Relevance of correction for drift and day-to-day variation in cystatin C measurement: a post-hoc analysis of the PREVEND cohort, with independent replication in the ESTHER cohortPriya Vart, Stephan J L Bakker, Ben Schöttker, et al.Kidney International|April 1, 2011
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal functionFrank A Holtkamp, Dick de Zeeuw, Merlin C Thomas, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 16, 2009
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study designHans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.European Heart Journal|October 27, 2009
N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general populationGerard C M Linssen, Stephan J L Bakker, Adriaan A Voors, et al.Pageof 34